Tag Archives: Biotech and Pharmaceuticals

250,000 kindergartners are vulnerable due to drop in vaccination rate

Nearly a quarter of a million kindergartners are vulnerable to measles due to a dip in vaccination coverage during the pandemic, according to the Centers for Disease Control and Prevention.

The CDC, in a report published Thursday, found that 93% of kindergartners were up to date with state-required vaccines during the 2021-22 school year, a decline of 2% from 2019-20.

“While this might not sound significant, it means nearly 250,000 kindergartners are potentially not protected against measles,” Dr. Georgina Peacock, head of the CDC’s immunization services division, said during a call with reporters Thursday.

“And we know that measles, mumps and rubella vaccination coverage for kindergartners is the lowest it has been in over a decade,” Peacock said.

Kindergartners are required to be vaccinated against measles, mumps and rubella; chickenpox; polio; and diphtheria, tetanus and pertussis. The vaccination rate for measles, mumps and rubella was 93.5% during the 2021-22 school year, below the target coverage of 95% to prevent outbreaks.

An ongoing measles outbreak in Columbus, Ohio, has spread to 83 children, 33 of whom were hospitalized. None of the children have died. The overwhelming majority of the kids, 78, were not vaccinated.

“These outbreaks harm children and cause significant disruptions in their opportunities to learn and grow and thrive,” said Dr. Sean O’Leary, who heads the American Academy of Pediatrics committee on infectious disease. “This is alarming and it should be a call to action for all of us.”

The CDC report looked at whether the kindergartners had received the second dose of their measles, mumps and rubella vaccine. Two doses are 97% effective at preventing disease and one dose is about 93% effective, according to the CDC.

Measles is a highly contagious virus that spreads when someone coughs or sneezes and contaminates the air, where the virus can linger for up to two hours. It can also spread when a person touches a contaminated surface and then touches their eyes, nose or mouth.

The virus is so contagious that a single person can spread the virus to 90% of people close to them who do not have immunity through vaccination or a previous infection, according to the CDC.

Measles can be dangerous for children younger than 5, adults older than 20, pregnant women, and people with compromised immune systems.

About 1 in 5 unvaccinated people who catch it are hospitalized. About 1 in 20 kids get pneumonia, and one in 1,000 have brain swelling that can cause disabilities. Symptoms begin with a high fever, cough, runny nose and red eyes. White spots appear in the mouth two to three days later, and a rash breaks out on the body.

CDC officials said disruptions to schools and the health-care system during the Covid pandemic are largely responsible for the decline in vaccination rates.

“We know that the pandemic really had a disruption to health-care systems,” Peacock said. “Part of it is that well-child visits maybe were missed and people are still trying to catch up on those well-child visits.”

“We know that the schools had a lot of things to focus on and in some cases maybe they were not able to gather all that documentation on the vaccinations,” Peacock said. “Or because children were at home for a lot of the pandemic, that may have not been the emphasis while they were focused on testing and doing all those other things related to the pandemic.”

In a separate report published Thursday, the CDC found that coverage for what’s known as the combined seven-vaccine series actually increased slightly among children born in 2018-19 by the time they turned two, compared with kids born in 2016-17.

This seven-vaccine series includes shots against measles, chickenpox, polio, hepatitis B, streptococcus pneumoniae, haemophilus influenzae or Hib, and diphtheria, tetanus and pertussis.

However, the CDC found that there were major income and racial disparities. Vaccination coverage declined by up to 5% during the pandemic for those living below the poverty level or in rural areas. Black and Hispanic children had lower vaccination rates than white children.

O’Leary said that while misinformation about vaccines is a problem, the vast majority of parents are still getting their kids vaccinated. He said inequality is the bigger issue.

“The things we really need to focus on are addressing access and child poverty,” O’Leary said.

Read original article here

Pfizer CEO says there will be no generic Paxlovid for China

An online pharmacy lists Pfizer’s oral anti-Covid drug Paxlovid for 2,980 yuan per box in in Suqian, Jiangsu province, China on Dec. 13, 2022.

CFOTO | Future Publishing | Getty Images

Pfizer is not in talks with Chinese authorities to license a generic version of its Covid-19 treatment Paxlovid for use there, but is in discussions about a price for the branded product, Chief Executive Albert Bourla said on Monday.

Reuters reported on Friday that China was in talks with Pfizer to secure a license that will allow domestic drugmakers to manufacture and distribute a generic version of the U.S. firm’s Covid-19 antiviral drug Paxlovid in China.

related investing news

Referring to that report, Bourla speaking at JPMorgan’s healthcare conference in San Francisco, said “We are not in discussions. We have an agreement already for local manufacturing of Paxlovid in China. So we have a local partner that will make Paxlovid for us, and then we will sell it to the Chinese market.”

Bourla said the company had shipped thousands of courses of the treatment in 2022 to China and in the past couple of weeks, had increased that to millions.

On Sunday, China’s Healthcare Security Administration (NHSA) said that the country would not include Paxlovid in an update to its list of medicines covered by basic medical insurance schemes as the U.S. firm quoted a high price for the Covid-19 drug.

CNBC Health & Science

Read CNBC’s latest global health coverage:

Bourla said that talks with China on future pricing for the treatment had broken off after China had asked for a lower price than Pfizer is charging for most lower middle income countries.

“They are the second highest economy in the world and I don’t think that they should pay less than El Salvador,” Bourla said.

Still, Bourla said the removal from the list would not have an effect on the company’s business there until April. He said the company had shipped millions of courses of the drug to China in recent weeks.

The company could end up selling only to the private market in China, he said.

Read original article here

BioNTech says it will start cancer vaccine trials in the UK from September

A NHS vaccinator administers the Pfizer-BioNTech Covid-19 booster jab to a woman, at a vaccination centre in London. BioNTech is launching a large-scale trial of mRNA therapies to treat cancer and other diseases in the U.K.

Sopa Images | Lightrocket | Getty Images

LONDON — The U.K. government on Friday announced a partnership with German firm BioNTech to test potential vaccines for cancer and other diseases, as campaigners warned any breakthrough must remain affordable and accessible.

Cancer patients in England will get early access to trials involving personalized mRNA therapies, including cancer vaccines, which aim to spur the immune system to attack harmful cells.

They will be administered to early and late-stage patients and target both active cancer cells and preventing their return.

BioNTech will set up new research and development centers in the U.K., with a lab in Cambridge and headquarters in London, and aim to deliver 10,000 therapies to patients from September 2023 until the end of the decade.

The company developed one of the most widely-distributed Covid-19 vaccines alongside U.S. pharma firm Pfizer. Its CEO, Ugur Sahin, said it had learned lessons from the coronavirus pandemic about collaboration between the British National Health Service, academics, regulators and the private sector in the development of drugs that it was applying now.

“Our goal is to accelerate the development of immunotherapies and vaccines using technologies we have been researching for over 20 years,” he said in a statement. “The collaboration will cover various cancer types and infectious diseases affecting collectively hundreds of millions of people worldwide.”

Peter Johnson, Britain’s National Clinical Director for Cancer, said mRNA technology had the potential to transform approaches to a number of illnesses.

The government confirmed to CNBC the announcement represented a private investment into the U.K., but would be supported by a new Cancer Vaccine Launch Pad funded by the NHS.

Other mRNA cancer vaccines, including a collaboration between U.S. firms Moderna and Merck, are also being trialed.

Tim Bierley, a campaigner at U.K.-based group Global Justice Now, said big pharmaceutical companies had “terrible record of price gouging on new medicines, even where public money has played a key role in bringing them to the market.”

“The government has a moral duty to push BioNtech to set the price of this potentially life-saving vaccine so it is accessible to all,” he said.

CNBC Health & Science

Read CNBC’s latest global health coverage:

Mohga Kamal-Yanni, policy co-lead for the People’s Vaccine Alliance — a global group of health organizations, economists and activists — said news of the trial was good, but that any outcome “belongs to the people” due to the amount of public funding involved.

“The U.K. government must say how it will ensure any new medicine, vaccine or technology will be made available and affordable to developing countries,” Kamal-Yanni said.

A government spokesperson told CNBC the research was at too early a stage to discuss pricing and distribution, but pointed to its record in distributing free Covid-19 vaccines.

Read original article here

BioNTech says it will start cancer vaccine trials in the UK from September

A NHS vaccinator administers the Pfizer-BioNTech Covid-19 booster jab to a woman, at a vaccination centre in London. BioNTech is launching a large-scale trial of mRNA therapies to treat cancer and other diseases in the U.K.

Sopa Images | Lightrocket | Getty Images

LONDON — The U.K. government on Friday announced a partnership with German firm BioNTech to test potential vaccines for cancer and other diseases, as campaigners warned any breakthrough must remain affordable and accessible.

Cancer patients in England will get early access to trials involving personalized mRNA therapies, including cancer vaccines, which aim to spur the immune system to attack harmful cells.

They will be administered to early and late-stage patients and target both active cancer cells and preventing their return.

BioNTech will set up new research and development centers in the U.K., with a lab in Cambridge and headquarters in London, and aim to deliver 10,000 therapies to patients from September 2023 until the end of the decade.

The company developed one of the most widely-distributed Covid-19 vaccines alongside U.S. pharma firm Pfizer. Its CEO, Ugur Sahin, said it had learned lessons from the coronavirus pandemic about collaboration between the British National Health Service, academics, regulators and the private sector in the development of drugs that it was applying now.

“Our goal is to accelerate the development of immunotherapies and vaccines using technologies we have been researching for over 20 years,” he said in a statement. “The collaboration will cover various cancer types and infectious diseases affecting collectively hundreds of millions of people worldwide.”

Peter Johnson, Britain’s National Clinical Director for Cancer, said mRNA technology had the potential to transform approaches to a number of illnesses.

The government confirmed to CNBC the announcement represented a private investment into the U.K., but would be supported by a new Cancer Vaccine Launch Pad funded by the NHS.

Other mRNA cancer vaccines, including a collaboration between U.S. firms Moderna and Merck, are also being trialed.

Tim Bierley, a campaigner at U.K.-based group Global Justice Now, said big pharmaceutical companies had “terrible record of price gouging on new medicines, even where public money has played a key role in bringing them to the market.”

“The government has a moral duty to push BioNtech to set the price of this potentially life-saving vaccine so it is accessible to all,” he said.

CNBC Health & Science

Read CNBC’s latest global health coverage:

Mohga Kamal-Yanni, policy co-lead for the People’s Vaccine Alliance — a global group of health organizations, economists and activists — said news of the trial was good, but that any outcome “belongs to the people” due to the amount of public funding involved.

“The U.K. government must say how it will ensure any new medicine, vaccine or technology will be made available and affordable to developing countries,” Kamal-Yanni said.

A government spokesperson told CNBC the research was at too early a stage to discuss pricing and distribution, but pointed to its record in distributing free Covid-19 vaccines.

Read original article here

omicron XBB.1.5 is immune evasive, binds better to cells

Gilnature | Istock | Getty Images

The Covid omicron XBB.1.5 variant is rapidly becoming dominant in the U.S. because it is highly immune evasive and appears more effective at binding to cells than related subvariants, scientists say.

XBB.1.5 now represents about 41% of new cases nationwide in the U.S., nearly doubling in prevalence over the past week, according to the data published Friday by the Centers for Disease Control and Prevention. The subvariant more than doubled as a share of cases every week through Dec. 24. In the past week, it nearly doubled from 21.7% prevalence.

Scientists and public health officials have been closely monitoring the XBB subvariant family for months because the strains have many mutations that could render the Covid-19 vaccines, including the omicron boosters, less effective and cause even more breakthrough infections.

XBB was first identified in India in August. It quickly become dominant there, as well as in Singapore. It has since evolved into a family of subvariants including XBB.1 and XBB.1.5.

Andrew Pekosz, a virologist at Johns Hopkins University, said XBB.1.5 is different from its family members because it has an additional mutation that makes it bind better to cells.

“The virus needs to bind tightly to cells to be more efficient at getting in and that could help the virus be a little bit more efficient at infecting people,” Pekosz said.

Yunlong Richard Cao, a scientist and assistant professor at Peking University, published data on Twitter Tuesday that indicated XBB.1.5 not only evades protective antibodies as effectively as the XBB.1 variant, which was highly immune evasive, but also is better at binding to cells through a key receptor.

Scientists at Columbia University, in a study published earlier this month in the journal Cell, warned that the rise of subvariants such as XBB could “further compromise the efficacy of current COVID-19 vaccines and result in a surge of breakthrough infections as well as re-infections.”

The XBB subvariants are also resistant to Evusheld, an antibody cocktail that many people with weak immune systems rely on for protection against Covid infection because they don’t mount a strong response to the vaccines.

The scientists described the resistance of the XBB subvariants to antibodies from vaccination and infection as “alarming.” The XBB subvariants were even more effective at dodging protection from the omicron boosters than the BQ subvariants, which are also highly immune evasive, the scientists found.

CNBC Health & Science

Read CNBC’s latest global health coverage:

Dr. David Ho, an author on the Columbia study, agreed with the other scientists that XBB.1.5 probably has a growth advantage because it binds better to cells than its XBB relatives. Ho also said XBB.1.5 is about as immune evasive as XBB and XBB.1, which were two of the subvariants most resistant to protective antibodies from infection and vaccination so far.

Dr. Anthony Fauci, who is leaving his role as White House chief medical advisor, has previously said that the XBB subvariants reduce the protection the boosters provide against infection “multifold.”

“You could expect some protection, but not the optimal protection,” Fauci told reporters during a White House briefing in November.

Fauci said he was encouraged by the case of Singapore, which had a major surge of infections from XBB but did not see hospitalizations rise at the same rate. Pekosz said XBB.1.5, in combination with holiday travel, could cause cases to rise in the U.S. But he said the boosters appear to be preventing severe disease.

“It does look like the vaccine, the bivalent booster is providing continued protection against hospitalization with these variants,” Pekosz said. “It really emphasizes the need to get a booster particularly into vulnerable populations to provide continued protection from severe disease with these new variants.”

Health officials in the U.S. have repeatedly called on the elderly in particular to make sure they are up to date on their vaccines and get treated with the antiviral Paxlovid if they have a breakthrough infection.

Read original article here

CDC expands BMI charts for severely overweight kids

The Centers for Disease Control and Prevention on Thursday released new body mass index charts for children in response to the growing obesity crisis in the U.S.

The previous BMI chart for children ages 2 to 19, published in 2000, is based on data from 1963 to 1980, but obesity and severe obesity in children has increased significantly since the ’80s. More than 4.5 million children and teenagers had severe obesity in 2018, according to the CDC.

BMI is calculated using a mathematical formula that measures body fat, generally by dividing an individual’s height by their weight. For adults, a healthy BMI runs from 18.5 to 24.9, or 111 lbs. to about 150 lbs. for someone who is 5’5″. At 5’10”, a healthy BMI runs between 129 lbs. and 175 lbs. For adults ages 20 and older, a BMI of 30 and above is considered obese.

The previous charts for children did not go beyond a BMI of 37. The new charts extend to a BMI of 60 and measure whether it falls within healthy parameters based on a percentile measured against other children of the same age and gender.

“Prior to today’s release, the growth charts did not extend high enough to plot BMI for the increasing number of children with severe obesity,” said Dr. Karen Hacker, director of the CDC’s National Center for Chronic Disease Prevention and Health Promotion.

BMI for kids up to 20-year-olds runs along a sliding range, depending on age and gender. Under the new guidelines, healthy BMI for kids can range from as low as around 13 to about 17 for a 6-year-old girl or boy to a range of as much as roughly 18 to around 26 for a 20-year-old young woman.

The extended charts will help health-care providers work with families to treat children who are suffering from obesity, Hacker said. The BMI charts from 2000 will still be used for children who are not obese, according to the CDC.

Obesity has increased significantly among children over the past 40 years. During the four-year period ended in 1980, 5.5% of children ages 2 to 19 were obese and 1.3% were severely obese. By 2018, 19.3% of kids were obese and 6.1% were severely obese, according to National Center for Health Statistics.

Obesity for children is defined as a BMI that is higher than 95% of kids of the same age and gender, according to the CDC. Severe obesity is a BMI that is 120% higher than the 95th percentile.

Although children’s BMI is calculated using the same formula as adults, a healthy weight is measured in relation to other kids of the same age and gender. This is because children’s height and weight can vary significantly as they grow.

Read original article here

BQ, XBB omicron subvariants pose serious threat to boosters

Evusheld injection, a new COVID treatment that people can take before becoming symptomatic, in Chicago on Friday, Feb. 4, 2022.

Chris Sweda | Tribune News Service | Getty Images

The omicron subvariants that have become dominant in recent months present a serious threat to the effectiveness of the new boosters, render antibody treatments ineffective and could cause a surge of breakthrough infections, according to a new study.

The BQ.1, BQ.1.1, XBB and XBB.1 omicron subvariants are the most immune evasive variants of Covid-19 to date, according to scientists affiliated with Columbia University and the University of Michigan. These variants, taken together, are causing 72% of new infections in the U.S. right now, according to data from the Centers for Disease Control and Prevention.

related investing news

The scientists, in a study published online Tuesday in the peer-reviewed journal Cell, found that these subvariants are “barely susceptible to neutralization” by the vaccines, including the new omicron boosters. The immune response of people who were vaccinated and had breakthrough infections with prior omicron variants was also weaker against the subvariants.

“Together, our findings indicate that BQ and XBB subvariants present serious threats to current COVID-19 vaccines, render inactive all authorized antibodies, and may have gained dominance in the population because of their advantage in evading antibodies,” the scientists wrote.

Although these subvariants are more likely to cause breakthrough infections, the vaccines have been shown to remain effective at preventing hospitalization and severe disease from omicron, the scientists wrote.

The study examined blood samples from people who received three or four shots of the original vaccines, those who received the new omicron boosters after three shots of the original vaccines, and individuals vaccinated with the original shots who also had breakthrough infections from the BA.2 or BA.5 subvariants.

For people who received the omicron boosters, antibodies that block infection were 24 times lower against BQ.1, 41 times lower against BQ.1.1, 66 times lower against XBB and 85 times lower against XBB.1 compared to their performance against the ancestral strain that emerged in Wuhan, China in 2019.

However, people who received the omicron boosters had modestly higher antibody levels against all of these subvariants compared with people who received three or four shots of the original vaccines, according to the study.

People who were vaccinated and had breakthrough infections had the highest antibody levels of any group in the study, though neutralization was also much lower against the subvariants than the ancestral strain.

The subvariants have evolved away from previous versions of omicron in dramatic fashion. BQ.1.1, for example, is about as different from omicron BA.5 as the latter subvariant is from ancestral Covid strain, according to the study.

“Therefore, it is alarming that these newly emerged subvariants could further compromise the efficacy of current COVID-19 vaccines and result in a surge of breakthrough infections, as well as re-infections,” the scientists wrote.

XBB.1, however, presents the biggest challenge. It is about 49 times more resistant to antibody neutralization than the BA.5 subvariant, according to the study. XBB.1, fortunately, is currently causing no more than 1% of infections in the U.S., according to CDC data.

BQ.1.1 and BQ.1 represent 37% and 31% of new infections respectively, while XBB is causing 4.7% of new infections, according to CDC data.

Antibodies ineffective

Key antibody drugs, Evusheld and bebtelovimab, were “completely inactive” against the new subvariants, according to the study. These antibodies are used primarily by people with weak immune systems.

Evusheld is an antibody cocktail used to prevent Covid in people with weak immune systems who don’t respond strongly to the vaccines. Bebtelovimab is used to prevent Covid from progressing to severe disease in organ transplant patients and other individuals who cannot take other treatments.

“This poses a serious problem for millions of immunocompromised individuals who do not respond robustly to COVID-19 vaccines,” the scientists wrote. “The urgent need to develop active monoclonal antibodies for clinical use is obvious.”

The FDA has already pulled its authorization of bebtelovimab nationwide because it is no longer effective against the dominant omicron variants in the U.S. Evusheld remains authorized as the only option for pre-exposure prophylaxis.

New Covid infections increased by about 50% to 459,000 for the week ending Dec. 7, according to CDC data. Covid deaths increased 61% to nearly 3,000 during the same week. Hospital admissions have plateaued at 4,700 per day on average after rising in November, according to the data.

White House chief medical advisor Dr. Anthony Fauci, in a press briefing last month, said U.S. health officials are hoping there’s enough immunity in the population from vaccination, infection or both to prevent the massive surge of infections and hospitalizations the U.S. suffered last winter when omicron first arrived.

CNBC Health & Science

Read CNBC’s latest global health coverage:

Read original article here

Strep A antibiotics prices, shortages hit drugstores amid UK outbreak

Drugstores are warning of major shortages of key antibiotics used to treat Strep A, as cases rise in the U.K.

Marko Geber | Digitalvision | Getty Images

LONDON — Drugstores in Britain are warning of shortages of key antibiotics used to treat Strep A, as cases rise and the number of child fatalities reaches 15.

A surge in Group A Streptococcus, especially among schoolchildren, has increased demand for amoxicillin and penicillin, the main antibiotic treatments, over the past week.

Where supplies do exist, they are “flying off the shelves,” according to drugstores, with some saying they are now dispensing medication at a loss due to soaring wholesale prices.

In some cases, pharmacists say wholesale prices for the drugs have spiked as much as 850%. These increased costs must be absorbed either by the U.K.’s National Health Service or drugstores, rather than parents, who typically receive children’s prescriptions for free.

At least 15 children have died in the U.K. from severe cases of Strep A this winter season, according to health agencies across England, Wales and Northern Ireland. A further death from suspected infection was reported Saturday but has not yet been confirmed.

While most cases of Strep A are mild and often go unnoticed, it can also lead to more serious illness and complications, such as scarlet fever. The bacteria can also get into the bloodstream and cause an illness called invasive Group A strep (iGAS). 

These severe infections can be deadly, and are thought to be the cause of the recent spate of deaths. It has led to an increase in clinicians prescribing antibiotics for children.

Cases have been on the rise in Britain this year, with the U.K. Health Security Agency reporting 6,602 cases of scarlet fever from Sept. 12 to Dec. 4, well above the 2,538 reported during the last peak in 2017-2018.

Fears of a national shortage

The government and wholesalers have insisted that the country is adequately equipped to deal with the outbreak. Prime Minister Rishi Sunak last week dismissed fears of a “national shortage” of antibiotics.

“There are no current shortages of drugs available to treat this and there are well-established procedures in place to ensure that that remains the case,” he told the House of Commons on Wednesday.

However, a letter to pharmacists from NHS England, seen by Sky News, acknowledged that local drugstores may be experiencing a “temporary interruption of supply of some relevant antibiotics due to increased demand.”

Dr. Leyla Hannbeck, chief executive of the Association of Independent Multiple Pharmacies (AIMP), which represents drugstore owners nationwide, told CNBC the reality on the ground was becoming desperate.

This just shows the incompetence of those in charge. This is not the first time this has happened.

Dr Leyla Hannbeck

CEO, Association of Independent Multiple Pharmacies

“Quite clearly there isn’t (enough supply), because it’s not finding its way to pharmacies,” she said. “And where there are patchy supplies, they are flying off the shelves.”

“This is very concerning for us, especially when we have parents coming into pharmacies, and unfortunately they haven’t got the stock,” she added.

Parents have been advised to call ahead to drugstores to check prescription availability after Hannbeck noted reports of families traveling for miles between stores.

She said the government shouldn’t be surprised by the shortages given similar shortfalls in medication for other outbreaks, such as monkeypox, earlier this year.

“This just shows the incompetence of those in charge,” she said. “This is not the first time this has happened. Since the beginning of this year, I have been discussing with community pharmacies that there is something the matter with the U.K.’s drug supply chains.”

The U.K. health department did not comment on allegations of incompetence when contacted by CNBC.

Drugstores ‘footing the bill’

Drug supply chains have been heavily disrupted this year due to a combination of factors including Russia’s invasion of Ukraine, inflation, Covid-19 and Brexit.

It has left drugstores spending more time — and money — sourcing medications.

Under the U.K.’s National Health Service (NHS) drug tariff scheme, drugstores receive set compensation for medication. There is also a concession list of medications for which higher prices can be paid.

Despite this, when wholesale prices jump, drugstores can end up making a loss.

The government’s Department of Health and Social Care has warned that, while prices may fluctuate, “no company should use this as an opportunity to exploit the NHS.”

Streptococcus A — or Group A Strep (GAS) — is a bacterial infection of the throat or skin, which typically arises during the winter months.

Halfpoint Images | Moment | Getty Images

However, over the past week, wholesale prices for amoxicillin and penicillin liquid solutions — which provide an alternative to tablets for children and are in particularly short supply — have risen in some places from around £2 to between £15 and £19, according to AIMP’s Hannbeck.

London-based drug wholesaler Sigma Pharmaceuticals reportedly hiked the price of its amoxicillin liquid solution by more than 10 times to £19 on Thursday, but later told CNBC the surge was due to an “IT glitch.”

Martin Sawer, executive director at the Healthcare Distribution Association, which represents drug wholesalers, said higher prices “directly reflect” the increased costs charged by manufacturers. He rejected claims of supply shortfalls, pointing instead to a “huge demand surge.”

“Right now there is too much demand for products and not enough competitive products being made available to buy from the manufacturers,” Sawer said.

If Government doesn’t intervene soon to protect pharmacies, patients can expect to see ever more problems with receiving their medicines.

Janet Morrison

chief executive, Pharmaceutical Services Negotiating Committee

Drugstore owners are now calling for the government to update its concessionary price for amoxicillin and penicillin, to ensure they are fairly reimbursed even if prices rise further.

Janet Morrison, chief executive of the Pharmaceutical Services Negotiating Committee, which negotiates the concessions list with the health department, said pricing assistance was “urgently” needed.

“Pharmacy teams are at breaking point,” she said. “They are helpless against market forces that are working against them, and urgently need Government assurance that all medicines will be available, and not at wildly inflated prices.”

A total of 158 drugs were on the NHS’s November concessions list, compared to 135 in October. Morrison said she expects to see a “record number” of medicines added to the list in December as supply constraints exacerbate shortages and push drug prices even higher.

“For months on end, pharmacies have been footing the bill for NHS medicines themselves when these should be covered by Government,” said Morrison.

“This can’t continue,” she added. “If Government doesn’t intervene soon to protect pharmacies, patients can expect to see ever more problems with receiving their medicines. Government and the NHS must fix this, and fast.”

Read original article here

CDC encourages people to wear masks to prevent spread of Covid, flu, RSV

The Centers for Disease Control Prevention on Monday encouraged people to wear masks to help reduce the spread of respiratory illnesses this season as Covid, flu and RSV circulate at the same time.

CDC Director Dr. Rochelle Walensky, in a call with reporters, said wearing a mask is one of several everyday precautions that people can take to reduce their chances of catching or spreading a respiratory virus during the busy holiday season.

“We also encourage you to wear a high-quality, well-fitting mask to prevent the spread of respiratory illnesses,” said Walensky, adding that people living in areas with high levels of Covid transmission should especially consider masking.

The CDC director said the agency is considering expanding its system of Covid community levels to take into account other respiratory viruses such as the flu. The system is the basis for when CDC advises the public to wear masks. But Walensky encouraged people to take proactive action.

“One need not wait on CDC action in order to put a mask on,” Walensky said. “We would encourage all of those preventive measures — hand washing, staying home when you’re sick, masking, increased ventilation — during respiratory virus season, but especially in areas of high Covid-19 community levels.”

About 5% of the U.S. population lives in counties where the CDC is officially recommending masks due to high Covid levels. The CDC continues to recommend masking for anyone travelling by plane, train, bus or other forms of public transportation, Walensky said.

People with weak immune systems and those who otherwise face a heightened risk of severe disease should also consider wearing a mask, the CDC director said.

Walensky strongly encouraged everyone eligible to receive their flu shot and Covid booster. Flu vaccination coverage is lagging for at-risk groups — children under age 5, pregnant women, and at-risk seniors — compared with last year, the CDC director said. There is no vaccine for RSV.

“I want to emphasize that the flu vaccine can be life saving and importantly, there’s still time to get vaccinated to be protected against flu this season and its potential serious consequences,” Walensky said.

The flu has arrived early and hit the U.S. hard with hospitalizations at a decade high for this time of year. More than 8.7 million people have fallen ill, 78,000 have been hospitalized, and 4,500 people have died from the flu this season, according to CDC data. Fourteen children have died from the flu so far this season.

More than 19,000 people were hospitalized with the flu during the week ending Nov. 26, nearly double the previous week, according to CDC data.

People hospitalized with Covid also increased 27% during the week ending Dec. 2, according to CDC data. And respiratory syncytial virus, or RSV, has been hospitalizing children at higher rate than in previous years. Walensky said RSV appears to have peaked in the Southeast and may be leveling off in the Mid-Atlantic, though circulation of the virus remains high in much of the nation.

“We now face yet another surge of illness. Another moment of overstretched capacity and really one of tragic and often preventable death,” Walensky said, as she thanked health-care workers for their service during the repeated surges of illness they have confronted since the Covid pandemic began.

Dr. Sandra Fryhofer, board chair of the American Medical Association, said the circulation of Covid, flu and RSV at the same is a “a perfect storm for a terrible holiday season.” Fryhofer said she understands many people are tired of receiving repeated Covid shots, but getting vaccinated is the best way to avoiding falling ill over the holidays.

“You could get really, really sick this year and ruin your holiday celebrations if you don’t get vaccinated,” Fryhofer said during Monday’s call.

The Children’s Hospital Association and the American Academy of Pediatrics last month asked the Biden administration to declare a public health emergency in response to the surge of pediatric hospitalizations from RSV and the flu.

Read original article here

Biden administration will end monkeypox public health emergency

People line up to get a monkeypox vaccination at a new walk-up monkeypox vaccination site at Barnsdall Art Park on Tuesday, Aug. 9, 2022 in Hollywood, CA. 

Brian Van Der Brug | Los Angeles Times | Getty Images

The Biden administration will end the public health emergency declared in response to the monkeypox outbreak, as new infections have declined dramatically and vaccination rates have increased.

The Health and Human Services Department does not expect it will renew the emergency declaration after it expires on Jan. 31 “given the low number of cases today,” HHS Secretary Xavier Becerra said in a statement Friday.

“But we won’t take our foot off the gas — we will continue to monitor the case trends closely and encourage all at-risk individuals to get a free vaccine,” he said. “As we move into the next phase of this effort, the Biden-Harris Administration continues working closely with jurisdictions and partners to monitor trends, especially in communities that have been disproportionately affected.”

Becerra declared an emergency in August in an effort to accelerate a vaccination and education campaign as the virus was spreading swiftly in the gay community. The spread of the virus, dubbed “mpox” on Monday by the World Health Organization in order to reduce stigma associated with its name, has slowed drastically since.

Mpox has infected nearly 30,000 people and killed 15 in the U.S. since health officials confirmed the first domestic case in May, according to the Centers for Disease Control and Prevention. The U.S. outbreak is the largest in the world.

But infections have slowed dramatically since August, when new cases peaked at 638 per day on average. The U.S. is currently averaging about seven new cases a day, according to CDC data.

U.S. health officials have said the outbreak has slowed because vaccinations have increased dramatically, and people have changed their behavior in response to education campaigns about how to avoid infection.

CNBC Health & Science

Read CNBC’s latest global health coverage:

The vaccination campaign got off to a rocky start, with limited supplies resulting in long lines at clinics and protests in some cities. But vaccinations increased significantly after the White House created a task force and HHS declared a public health emergency.

More than 1.1 million doses of the Jynneos vaccine have been administered in the U.S. since the summer. CDC Director Dr. Rochelle Walensky has said about 1.7 million gay and bisexual people who are HIV positive or are taking medication to prevent HIV infection are at highest risk from mpox.

Mpox has spread primarily through sexual contact among men who have sex with men. The virus causes rashes resembling pimples or blisters that can develop in sensitive areas and be very painful. Though mpox is rarely fatal, people with compromised immune systems are at higher risk of severe disease.

The CDC, in a report published in late October, said it is unlikely the U.S. will eradicate mpox in the near future. The virus will probably continue to circulate at low level primarily in communities of men who have sex with men, according to CDC. Though anyone can catch mpox, there’s little evidence of the virus spreading widely in the general population so far, according to CDC.

The global mpox outbreak this year is the largest in history with more than 80,000 confirmed cases in more than 100 countries. The current outbreak is highly unusual because the virus is spreading widely between people in Europe and North America.

Historically, mpox spread at low levels in remote areas of West and Central Africa where people caught the virus from infected animals.

Read original article here